Cholesterol metabolism modulators in future drug therapy for atherosclerosis;Modulateurs du métabolisme du cholestérol et avenir du traitement de l'athérosclérose

Medecine/Sciences

Volumn 21, Issue SPEC. ISS. DEC., 2005, Pages 53-58

  Morozova, Svetlana ^a   Suc Royer, Isabelle ^a   Auwerx, Johan ^b  

^a Laboratoires Fournier SA   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ABC TRANSPORTER A1; AVASIMIBE; CD36 ANTIGEN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LE S 8921; LIVER X RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROBUCOL SUCCINATE; RECEPTOR BLOCKING AGENT; SCAVENGER RECEPTOR BI; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL METABOLISM; DRUG RESEARCH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INDUSTRIALIZATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; STROKE;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; BILE ACIDS AND SALTS; CHOLESTEROL; HUMANS; INTESTINAL ABSORPTION;

EID: 29944434397     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-96.
2. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-58.
3. Lusis AJ. Atherosclerosis. Nature 2000; 407: 233-41.
4. Assmann G, Cullen P, Jossa F, et al. Coronary heart disease: Reducing the risk: The scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1819-24.
5. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: Triumphs, concerns, and opportunities. N Engl J Med 1997; 337: 1360-9.
6. Russell DW. Cholesterol biosynthesis and metabolism. Cardiovasc Drugs Ther 1992; 6: 103-10.
7. Ros E. Intestinal absorption of triglyceride and cholesterol. Dietary and pharmacological inhibition to reduce cardiovascular risk. Atherosclerosis 2000; 151: 357-79.
8. Bellosta S, Bernini F, Ferri N, et al. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 1998; 137: S101-9.
9. Davignon J. Advances in drug treatment of dyslipidemia: Focus on atorvastatin. Can J Cardiol 1998; 14(suppl B): 28B-38.
10. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: The role of statins. Am J Cardiol 1998; 82: 3J-10.
11. Ross SD, Allen IE, Connelly JE, et al. Clinical outcomes in statin treatment trials: A meta-analysis. Arch Intern Med 1999; 159: 1793-802.
12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-93.
13. van Heek M, Davis H. Pharmacology of ezetimibe. Eur Heart J 2002; 4(suppl): J5-8.
14. Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003; 107: 3124-8.
15. Sleight P. Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 2002; 89: 11A-7.
16. Evans M, Roberts A, Rees A. The future direction of cholesterol-lowering therapy. Curr Opin Lipidol 2002; 13: 663-9.
17. Brousseau ME, Schaefer EJ. New targets for medical treatment of lipid disorders. Curr Atheroscler Rep 2002; 4: 343-9.
18. Brown WV. Therapies on the horizon for cholesterol reduction. Clin Cardiol 2001; 24: III24-7.
19. Thompson GR, Naoumova RP. New prospects for lipid-lowering drugs. Exp Opin Invest Drugs 1998; 7: 715-27.
20. Pharmaproject. Richmond, Surrey (UK): PJB Publications, 2003.
21. Ugawa T, Kakuta H, Moritani H, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol 2000; 131: 63-70.
22. Chevy F, Illien F, Wolf C, Roux C. Limb malformations of rot fetuses exposed to a distal inhibitor of cholesterol biosynthesis. J Lipid Res 2002; 43: 1192-200.
23. Chang G, Ruggeri RB, Norwood HJ, Jr. Microsomal triglyceride transfer protein (MTP) inhibitors: Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curr Opin Drug Discov Dev 2002; 5: 562-70.
24. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol 2001; 431: 127-31.
25. Nicolosi RJ, Wilson TA, Krause BR. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters. Atherosclerosis 1998; 137: 77-85.
26. Accad M, Smith SJ, Newland DL, et al. Massive xanthomotosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA: Cholesterol acyltransferase 1. J Clin Invest 2000; 105: 711-9.
27. Willner EL, Tow B, Buhman KK, et al. Deficiency of acyl CoA: Cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 2003; 100: 1262-7.
28. Brewer HB Jr. The lipid-laden foam cell: An elusive target for therapeutic intervention.J Clin Invest 2000; 105: 703-5.
29. Ichihashi T, Izawa M, Miyata K, et al. Mechanism of hypocholesterolemic action of S-8921 in rats: S-8921 inhibits ileal bile acid absorption. J Pharmacol Exp Ther 1998; 284: 43-50.
30. Izzat NN, Deshazer ME, Loose-Mitchell DS. New molecular targets for cholesterol-lowering therapy. J Pharmacol Exp Ther 2000; 293: 315-20.
31. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97: 2917-23.
32. Okamoto H, Yonemori F, Wakitani K, et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406: 203-7.
33. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study. Circulation 2002; 105: 2159-65.
34. Repa JJ, Turley SD, Lobaccaro JA, et at. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 1524-9.
35. Joseph SB, McKilligin E, Pei L, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002; 99: 7604-9.
36. Lund EG, Menke JG, Sparrow CP. Liver X receptor agonists as potential therapeutic agents for dyslipidemia and atherosclerosis. Aterioscler Thromb Vasc Biol 2003; 23: 1169-77.
37. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717-26.
38. Klappacher GW, Glass CK. Roles of peroxisome proliferotor-activated receptor gamma in lipid homeostasis and inflammatory responses of macrophages. Curr Opin Lipidol 2002; 13: 305-12.
39. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002; 12: 2545-8.
40. Mashima R, Witting PK, Stocker R. Oxidants and antioxidants in atherosclerosis. Curr Opin Lipidol 2001; 12: 411-8.